Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zimmer Biomet Holdings, Inc. (NYSE: ZBH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zimmer Biomet is a global medical technology company focused on musculoskeletal health and orthopedic implants, and its filings offer detailed insight into its operations, capital structure, risk factors and governance.
Through this page, you can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss Zimmer Biomet’s product categories such as knees, hips, sports medicine, extremities, trauma, craniomaxillofacial and thoracic (S.E.T.), and technology and data, bone cement and surgical. These reports typically include segment and geographic sales information, descriptions of the company’s digital and robotic technologies, and management’s discussion and analysis.
You will also find current reports on Form 8-K covering material events, including quarterly earnings releases, new debt issuances, revolving credit agreements, acquisitions such as the merger with Monogram Technologies Inc., and other significant corporate developments. Filings describing the company’s notes and bonds, including series listed on the New York Stock Exchange, provide detail on interest rates, maturities, covenants and redemption features.
Stock Titan enhances these documents with AI-powered summaries that explain key points in clear language, helping users navigate complex topics like non-GAAP financial measures, leverage covenants and transaction structures. The platform also surfaces insider and executive-related filings, such as those reporting departures or appointments of certain officers, so users can track governance changes. With real-time updates from EDGAR and AI-generated highlights, this page is a focused resource for analyzing Zimmer Biomet’s SEC reporting history and ongoing regulatory disclosures.
Zimmer Biomet Holdings executive Wilfred Van Zuilen reported equity compensation activity involving restricted stock units and common shares. On
As part of the same vesting event, 828 common shares valued at
Zimmer Biomet Holdings, Inc. executive Chad F. Phipps reported routine equity compensation activity. On February 25, 2026, 2,626 restricted stock units were converted into an equal number of common shares at no cash exercise price as part of a scheduled vesting.
To cover tax withholding on the RSU vesting, 1,057 common shares were withheld by the company at a price of
Zimmer Biomet Holdings executive Yi Sang reported an equity award vesting and conversion. On February 25, 2026, 2,785 restricted stock units were exercised and converted into 2,785 shares of common stock at a stated price of $0.00 per share.
Following these transactions, Yi Sang directly held 5,567 restricted stock units and 22,837 shares of common stock. According to the vesting schedule, one-third of the RSUs vested on February 25, 2026, with the remaining units vesting one-half on each of February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported equity transactions tied to restricted stock units. On February 25, 2026, 2,347 RSUs were exercised into 2,347 shares of common stock at
Zimmer Biomet Holdings' Executive VP and CFO Suketu Upadhyay reported equity award activity involving restricted stock units and common shares. On February 25, 2026, he exercised 6,364 restricted stock units, converting them into 6,364 shares of common stock at a stated price of
Zimmer Biomet Holdings Chairman, President and CEO Ivan Tornos reported equity award activity involving restricted stock units and common shares of ZBH. He exercised or converted 19,090 restricted stock units into 19,090 shares of common stock at a price of
Zimmer Biomet Holdings officer Paul A. Stellato reported equity compensation activity involving restricted stock units (RSUs) and common shares. On February 25, 2026, 820 RSUs were exercised and converted into 820 shares of common stock at a stated price of
On the same date, 402 common shares were withheld at
Following these transactions, Stellato directly held 1,638 RSUs and 4,527 shares of common stock. The disposition was for tax withholding rather than an open-market sale.
Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. reported that officer Noor Jehanzeb received a grant of 10,076 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock. The award vests annually over three years in one-third increments starting on February 20, 2027.
ZIMMER BIOMET HOLDINGS, INC. officer Chad F. Phipps reported equity compensation and related share movements. On February 20, 2026, 2,246 restricted stock units were exercised into 2,246 shares of common stock at a price of $0.00 per share.
He was also granted 9,818 new restricted stock units, each representing a right to receive one common share, vesting annually over three years in one‑third installments starting February 20, 2027. To satisfy tax withholding on the RSU vesting, 942 common shares were disposed of at $98.62 per share through company share withholding, leaving him with 62,137 directly held common shares.
Thornal Kevin R reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. reported that executive Kevin R. Thornal, Group President–Global Business, received a grant of 27,385 restricted stock units (RSUs) on February 20, 2026. Each RSU represents a contingent right to receive one share of common stock and vests in three equal annual installments starting February 20, 2027.